RT Journal Article
SR Electronic
T1 Long-term prognosis of patients with cancer-related mutations in non-tumoral lung
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 3942
DO 10.1183/13993003.congress-2020.3942
VO 56
IS suppl 64
A1 Roberto Chalela
A1 Karys Khilzi
A1 Joaquín Gea
A1 Albert Sánchez-Font
A1 Lara Pijuan
A1 Jose Gregorio González-García
A1 Diana Badenes-Bonet
A1 Beatriz Bellosillo
A1 Víctor Curull
YR 2020
UL http://erj.ersjournals.com/content/56/suppl_64/3942.abstract
AB Introduction: In two previous cohorts we demonstrated that EGFR/KRAS mutations can be present in non-tumoral lung tissue (NTLT) regardless tumor genomic status. In cohort one (J Clin Med. 2019) the presence of these mutations was associated with a worse prognosis (disease-free survival), while in cohort two the presence of NTLT mutations in EGFR and KRAS was demonstrated even in the absence of mutations in the primary tumor (no differences in prognosis were found due to small sample size). The objective of this study is to analyze the 5-year prognosis of both cohorts and assess whether the presence of driver-mutations in NTLT is associated with a higher overall mortality in patients with localized ADC. We present the preliminary resultsMethods: 78 patients were included (47 from the first cohort and 31 from the second one). After tumor genotyping, the EGFR/KRAS status of the NTLT was performed with real-time PCRResults: two patients did not continued the follow-up. The remaining completed the 36-months follow-up and 77% have completed the 5-year follow-up at the time of the analysis. 13 (16.7%) patients had mutations in the EGFR and/or KRAS in the NTLT (M-NTLT group). At 60 months, 53.8% of M-NTLT group patients had distant recurrence vs 32.3%. Overall mortality was higher in the M-NTLT group: average survival of 40.5 months vs 54.8 (-14.3 months, Log-rank p=0.003). These results are independent of the type of mutation, cancer treatment and preoperative stageConclusion: based on two single-center cohorts, we can conclude that in patients with localized ADC, having EGFR or KRAS mutations in NTLT is associated with a higher risk of death. These data reaffirm the results of our previous studiesFootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 3942.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).